Ovarian/Fallopian/Peritoneal

Relapsed or Refractory intolerant to standard care

CCT5048
Phase I Open
Label Dose
Escalation
Study of
CRX100 in
Advanced Solid Tumors

Pl: Dorigo
BioEclipse
Therapeutics
1st Priority

GYNOVA0053
Phase III
AVB-56-500 in
Combination with
Paclitaxel in
Platinum-Resistant
Recurrent Ovarian Cancer
Pl: Diver
Aravive Biologics, Inc.

VAR0211
Phase II/II
MORAb-202
FolateReceptor
Alpha-Targeting
Antibody-Drug Conjugate in
Selected Tumor Types
Pl: Berek
Pending

GYNOVA0054
Phase III Alpelisib (BYL719) in
Combination w/
Olaparib vs
Chemotherapy in
Platinum-Resistant or Refractory
Ovarian Cancers
Pl: Diver
Sponsor: Novartis
Pharmaceuticals, Corporation

2nd Priority

Recurrent

Platinum Resistant

Platinum Resistant or Refractory

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Link
Trial Posting
Extension Study
Immunotherapy
Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu